Aktienanalyse zu Abeona Therapeutics Inc (ABEO)ABEOAbeona Therapeutics Inc

Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. The Company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa. Its fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. Its development portfolio features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. Its AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases. Its pipeline programs include ABO-504 (Stargardt disease), ABO-503 (X-linked retinoschisis), ABO-505 (autosomal dominant optic atrophy), UX111 (Sanfilippo Syndrome Type A (MPS IIIA)), TSHA-102 (Rett Syndrome), and TSHA-118 (Infantile Batten Disease (CLN1 Disease)). It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Abeona Therapeutics Inc (ABEO) appears to be a good buy right now due to its recent clinical advancements and positive analyst ratings. The current price is $4.40, significantly below the analyst price target of $17 from Roth Capital, implying a potential upside of 286%. Additionally, Cantor Fitzgerald's target of $30 suggests a potential upside of 582%. The company has activated its eighth clinical site for ZEVASKYN trials, which could drive future revenue growth. However, a notable risk is the company's negative earnings per share (EPS) of -0.35 reported last quarter, indicating ongoing financial challenges.

8 analysts cover ABEO: 8 rate it Buy, 0 Hold and 0 Sell. The average price target is 25.17.